Les publications originales les plus récentes
Bobo M, Lefevre L, Mallet-Guy P, Chacon A, Eloit M, Chevallier P, Peterlin P, Mear JB, Marchand T, Gallego-Hernanz MP, Mokeddem C, Gyan E, Tanguy-Schmidt A, Vallet N; FHU GOAL. Infectious events in fit patients with relapsed or refractory acute myeloid leukemia treated with azacitidine-venetoclax or intensive chemotherapy. Int J Infect Dis. 2026 Jan 19:108412.
Demoy M, Bauvais M, Vely A, Nicol T, Riou J, Le Jeanne H, Bauduin A, Rambaud H, Boyer F, Geneviève F, Boussaroque A, Copin MC, Ugo V, Orvain C, Luque Paz D. CD34-positive circulating cells quantification during follow-up in myeloproliferative neoplasms. Ann Hematol. 2026 Jan 16;105(1):21.
PRODUCTION SCIENTIFIQUE
_______________________________________________2026_______________________________________________
Bobo M, Lefevre L, Mallet-Guy P, Chacon A, Eloit M, Chevallier P, Peterlin P, Mear JB, Marchand T, Gallego-Hernanz MP, Mokeddem C, Gyan E, Tanguy-Schmidt A, Vallet N; FHU GOAL. Infectious events in fit patients with relapsed or refractory acute myeloid leukemia treated with azacitidine-venetoclax or intensive chemotherapy. Int J Infect Dis. 2026 Jan 19:108412.
Demoy M, Bauvais M, Vely A, Nicol T, Riou J, Le Jeanne H, Bauduin A, Rambaud H, Boyer F, Geneviève F, Boussaroque A, Copin MC, Ugo V, Orvain C, Luque Paz D. CD34-positive circulating cells quantification during follow-up in myeloproliferative neoplasms. Ann Hematol. 2026 Jan 16;105(1):21.
_______________________________________________2025_______________________________________________
Boucher L, Rozalska L, Sorel N, Olivier G, Hernanz MPG, Cayssials E, Raimbault A, Chomel JC. Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation. Leuk Res. 2024 Feb;137:107439. doi: 10.1016/j.leukres.2024.107439.
Chevallier P, Thiebaut A, François S, Chantepie S, Rubio MT, Labussiere-Wallet H, Brissot E, Maillard N, Huynh A, Coiteux V, Jullien M, Garnier A, Le Bourgeois A, Peterlin P, Guillaume T. A phase II study of ponatinib for prevention of relapse after allogeneic transplantation in FLT3 internal tandem duplication mutation-positive (FLT3-ITD+) acute myeloid leukemia: the PONALLO trial. Haematologica. 2025 Oct 1;110(10):2525-2529.
Foucault A, Hérault O. ALDH Enzymes and Hematological Diseases: A Scoping Review of Literature. Discov Med. 2024 Dec;36(191):2313-2324.
Mosnier C, Bellal S, Cottin L, Boyer F, Lemoine S, Bachelot A, Argentin J, Pawlicki B, Copin MC, Jouanneau-Courville R, Malinge A, Riou J, Hunault-Berger M, Ugo V, Orvain C, Luque Paz D. Relationship between additional mutations at diagnosis and treatment response in patients with essential thrombocythemia. Blood Adv. 2025 Mar 25;9(6):1303-1311.
Muron C, Luque Paz D, Copin MC, Orvain C. Pleural Infiltration Revealing Post-Essential Thrombocythemia Acute Myeloid Leukaemia. EJHaem. 2025 Nov 12;6(6):e1108.
Orvain C. Does the regional use of intensive chemotherapy impact the outcome of adults with AML? BMJ Oncol. 2024 Jul 5;3(1):e000480
_______________________________________________2024_______________________________________________
Boucher L, Rozalska L, Sorel N, Olivier G, Hernanz MPG, Cayssials E, Raimbault A, Chomel JC. Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation. Leuk Res. 2024 Feb;137:107439. doi: 10.1016/j.leukres.2024.107439.
Foucault A, Hérault O. ALDH Enzymes and Hematological Diseases: A Scoping Review of Literature. Discov Med. 2024 Dec;36(191):2313-2324.
_______________________________________________2023_______________________________________________
Bachelot A, Bouvier A, Riou J, Thepot S, Giltat A, Nunes Gomes C, Paillassa J, Jouanneau-Courville R, Renard M, Beucher A, Cottin L, Wiber M, Ribourtout B, Geneviève F, Luque Paz D, Tanguy-Schmidt A, Ugo V, Hunault-Berger M, Blanchet O, Orvain C. Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores. Am J Hematol. 2023 Jun;98(6):922-931. doi: 10.1002/ajh.26917.
Declerck C, Giltat A, Boutemy R, Brisset-Dheilly M, Pelhatre A, Hunault-Berger M, Kempf M, Kouatchet A, Mahieu R, Tanguy-Schmidt A, Orvain C. Implementation of a new blood cultures sampling strategy in patients receiving intensive chemotherapy for acute leukemia and/or hematopoietic cell transplantation. Leuk Lymphoma. 2023 Jun;64(6):1204-1207. doi: 10.1080/10428194.2023.2196595.
Desprez C, Kouatchet A, Marchand T, Mear JB, Tadié JM, Peterlin P, Chevalier P, Canet E, Couturier MA, Guillerm G, Bodenes L, Gyan E, Villate A, Ehrmann S, Lebreton A, Lester MA, Fronteau C, Larhantec G, André V, Riou J, Hunault-Berger M, Schmidt-Tanguy A, Orvain C. Outcome of patients with newly diagnosed AML admitted to the ICU, including preemptive admission - a multi-center study. Ann Hematol. 2023 Jun;102(6):1383-1393. doi: 10.1007/s00277-023-05205-6.
Haméon C, Machet A, Drieu La Rochelle L, Vallet N, Lejeune J, Ravalet N, Cottier JP, Hérault O, Gyan E. Cerebral localization of chronic myelomonocytic leukemia and improvement with high-dose cytarabine: A case report. EJHaem. 2023 Jun 23;4(3):844-847.
Peterlin P, Garnier A, Le Bourgeois A, Guillaume T, Le Bris Y, Theisen O, Béné MC, Eveillard M, Rimbert M, Jullien M, Planche L, Gaschet J,
Chevallier P. Tocilizumab in combination with a standard induction chemotherapy in acute myeloid leukaemia patients (TOCILAM study): a
single-centre, single-arm, phase 1 trial. EClinicalMedicine. 2023 Sep 28;64:102254.
Ravalet N, Guermouche H, Hirsch P, Picou F, Foucault A, Gallay N, Martignoles JA, Beaud J, Suner L, Deswarte C, Lachot S, Rault E, Largeaud L, Gissot V, Béné MC, Gyan E, Delhommeau F, Herault O. Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals. Clin Immunol. 2023 Aug 9;255:109730.
_______________________________________________2022 ________________________________________________
Desprez, C., Riou, J., Peterlin, P., Marchand, T., Couturier, M.-A., Villate, A., Mear, J.-B., Chevalier, P., Guillerm, G., Gyan, E., Schmidt-Tanguy, A., Walter, R.B., Hunault-Berger, M., Orvain, C., 2022. Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia—a Grand Ouest Against Leukemia (GOAL) study. Leukemia 36, 2408–2417. https://doi.org/10.1038/s41375-022-01677-z
Drevin, G., Briet, M., Bazzoli, C., Gyan, E., Schmidt, A., Dombret, H., Orvain, C., Giltat, A., Recher, C., Ifrah, N., Guardiola, P., Hunault-Berger, M., Abbara, C., 2022. Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial. Pharmaceutics 14, 792. https://doi.org/10.3390/pharmaceutics14040792
Dulucq, S., Nicolini, F.E., Rea, D., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Coiteux, V., Lenain, P., Rigal-Huguet, F., Liu, J., Guerci-Bresler, A., Legros, L., Ianotto, J.-C., Gardembas, M., Turlure, P., Dubruille, V., Rousselot, P., Martiniuc, J., Jardel, H., Johnson-Ansah, H., Joly, B., Henni, T., Cayssials, E., Zunic, P., Berger, M.G., Villemagne, B., Robbesyn, F., Morisset, S., Mahon, F.-X., Etienne, G., 2022. Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial. haematol 107, 2859–2869. https://doi.org/10.3324/haematol.2022.280811
Gyan, E., Pigneux, A., Hunault, M., Peterlin, P., Carré, M., Bay, J.-O., Bonmati, C., Gallego-Hernanz, M.-P., Lioure, B., Bertrand, P., Vallet, N., Ternant, D., Darrouzain, F., Picou, F., Béné, M.-C., Récher, C., Hérault, O., 2022. Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML. Sci Rep 12, 9748. https://doi.org/10.1038/s41598-022-13626-y
Lacombe, V., Beucher, A., Urbanski, G., Le Corre, Y., Cottin, L., Croué, A., Bouvier, A., 2022. Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome. Exp Hematol Oncol 11, 6. https://doi.org/10.1186/s40164-022-00262-5
Lemoine, S., Mornet, C., Quintin-Roue, I., Rousselet, M.-C., Cottin, L., Georgeais, A., Dubouis, L., Boyer, F., Orvain, C., Caillon, C., Renard, M., Le Brun, V., Le Clech, L., Ianotto, J.-C., Génin, E., Burroni, B., Ugo, V., Paz, D.L., Lippert, E., 2022. Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis. haematol 107, 2725–2731. https://doi.org/10.3324/haematol.2022.280917
Roux, B., Picou, F., Debeissat, C., Koubi, M., Gallay, N., Hirsch, P., Ravalet, N., Béné, M.C., Maigre, M., Hunault, M., Mosser, J., Etcheverry, A., Gyan, E., Delhommeau, F., Domenech, J., Herault, O., 2022. Aberrant DNA methylation impacts HOX genes expression in bone marrow mesenchymal stromal cells of myelodysplastic syndromes and de novo acute myeloid leukemia. Cancer Gene Ther 29, 1263–1275. https://doi.org/10.1038/s41417-022-00441-w
Sureau, L., Buors, C., Ianotto, J.-C., Boyer, F., Tanguy-Schmidt, A., Roy, L., Cayssials, E., Cailly, L., Chomel, J.-C., Chauveau, A., Orvain, C., Mansier, O., Ranta, D., Robles, M., Gyan, E., Hérault, O., Nimubona, S., Marchand, T., Lippert, E., Riou, J., Ugo, V., Luque Paz, D., 2022. JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes. Blood Cancer J. 12, 56. https://doi.org/10.1038/s41408-022-00646-0